Researchers published evidence in Nature Communications that engineered vesicles can enhance oral antibiotic absorption while mitigating gut dysbiosis, offering a potential route to boost efficacy and reduce collateral microbiome damage. The study reports a vesicle delivery strategy that improves bioavailability of orally administered antibiotics and helps maintain microbial diversity in preclinical models. Oral antibiotic loss of efficacy and microbiome disruption are longstanding issues; engineered vesicles aim to protect drugs from degradation and target intestinal uptake. If translated to humans, the approach could change oral dosing paradigms and reduce antibiotic‑driven complications such as Clostridioides difficile infection.